ArticleFrontiers in medicine2026
Doxycycline treatment for drug-resistant
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Mycoplasma pneumoniae pneumonia (MPP) in children is a common respiratory infection, with rising concerns over macrolide-resistant strains. The aim of this study is to establish an effective diagnostic prediction model for refractory MPP (RMPP) and evaluate doxycycline as an alternative treatment for macrolide-unresponsive MPP (MUMPP). Methods: 106 children with RMPP receiving doxycycline and 73 children with MUMPP treated with azithromycin were retrospectively analyzed. For all patients, the detection of MP-DNA in BALF, alongside clinical criteria, served to confirm active MP infection and infer phenotypic macrolide unresponsiveness/resistance. Univariate and multivariate logistic regression analyses were then used to identify clinically available risk factors for the development of RMPP among these patients with MP pneumonia. Results: The doxycycline group had significantly shorter fever duration, fewer lavage procedures, reduced steroid use, and shorter hospital stays compared to the azithromycin group ( Conclusion: In children with MUMPP, doxycycline treatment is associated with superior clinical outcomes compared to azithromycin. A nomogram incorporating readily available clinical factors can effectively identify patients at risk of developing RMPP, supporting early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.